Company:Chugai Pharmaceutical Co.
From HandWiki
Short description: Japanese pharmaceutical company
 | |
 Headquarters in Nihonbashi Mitsui Tower | |
Native name | 中外製薬株式会社 |
|---|---|
Romanized name | Chūgai Seiyaku kabushiki gaisha |
| Type | Public KK |
| Industry | Pharmaceutical Industry, Business import, production and development of drugs for medical sales |
| Founded | March 8, 1943 |
| Headquarters | Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo On the registration Headquarter: Tokyo Kita (Tokyo) |
Key people | Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO |
| Revenue | 72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated (December 2007) |
| Parent | Hoffmann-La Roche (61.62%) |
| Website | www |
Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社 Chūgai Seiyaku kabushiki gaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014.[1] The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.
History
Timeline
This is a timeline of important events of Chugai Pharmaceutical.[2]
- 1925: Juzo Ueno founded Chugai Shinyaku Co. Ltd. and started importing and selling medicines
- 1927: Start of the first own production
- 1930: Salobrocanon, an analgesic (pain reliever) and antipyretic is launched
- 1937: Calcium bromide production begins
- 1943: Name changed to Chugai Pharmaceutical Co., Ltd. based in Tokyo
- 1944: Acquisition of Matsunaga Pharmaceutical Ltd. and construction of a plant in Matsunaga
- 1945: The headquarters, the factories in Ikebukuro, Sakai and Takada were destroyed in World War II, the headquarters were relocated to Takada, the factory in Takada was rebuilt
- 1946: Construction of the plant in Kamagiishi
- 1951: Guronsan®, a drug to detoxify and restore liver function is launched
- 1952: Varsan®, a perspiration insecticide is launched
- 1955: Chugai became a public company
- 1956: The stock is listed on the Tokyo Stock Exchange
- 1957: Construction of the Ukima plant
- 1960: Establishment of a research center (Takada Research Laboratory, Tokyo)
- 1967: Foundation of Fukushima Kasai Co Ltd.
- 1961 – Developed patents for synthesis of vitamin A
- 1969: The name of Fukushima Kasai Co Ltd. is changed to Eiko Kasei Co Ltd., after the merger of Fukushima Kasai Co Ltd. and Fukuma Kasau Co. Ltd.
- 1971: Construction of the factory in Fujieda
- 1975: Picibanil®, a cancer drug is launched
- 1982: Opening of a branch in New York
- 1986: Opening of a branch in London
- 1989: Acquisition of Gen-Probe Incorporated (USA)
- 1990: Epogin® launched
- 1995 – Released acute promyelocytic sphere of leukemia drug treatment Vesanoid®
- 1996 – Released anti-viral chemotherapeutic agent Hivid® (HIV reverse transcriptase inhibitor)
- 1997 – Released HIV protease inhibitor Invirase®
- 1999 – Released immunosuppressive agent Cellcept®
- 2000 – Released antiemetic drug Kytril®, developed to combating the side effects of chemotherapy
- 2001 – Produced anti-influenza virus Tamiflu (Roche)
- 2002: Start of the alliance with Roche
- 2003: Xeloda®, a cancer drug is launched
- 2005: Actemra® launched
- 2007: Copegus®, an antiviral, Avastin®, a cancer drug, and Tarceva®, a cancer drug launched
- 2011 – Produced Actemra®, a human IL-6 receptor monoclonal antibody for rheumatoid arthritis
- 2014: Launch of Kadcyla®, a cancer drug, Chugai Pharma China Co Ltd. founded
- 2015 – In March the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of US$205 million.[3]
- 2016: Cooperation between Osaka University and Chugai
- 2018: Tecentriq®, a cancer drug is launched
- 2020 – FDA approved satralizumab (Enspryng) for treatment of the orphan disease neuromyelitis optica[4]
See also
- Biotech and pharmaceutical companies in the New York metropolitan area
References
- ↑ Cortez, Michelle Fay; Matsuyama, Kanoko (25 August 2014). "Roche Said to Have Decided Against Bid for Rest of Chugai". Bloomberg. https://www.bloomberg.com/news/2014-08-24/roche-said-to-have-decided-against-bid-for-rest-of-chugai.html.
- ↑ "History of Chugai Pharmaceutical". December 23, 2015. https://www.chugai-pharm.co.jp/english/profile/history/index.html.
- ↑ Staff (2 March 2015). "Chugai to Co-Develop Athersys' Cell Therapy in Japan in Up-to-$205M Partnership". Genetic Engineering & Biotechnology News. http://www.genengnews.com/gen-news-highlights/chugai-to-co-develop-athersys-cell-therapy-in-japan-in-up-to-205m-partnership/81250978/. Retrieved 2016-06-11.
- ↑ "FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord". 17 August 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-rare-disease-affecting-optic-nerves-spinal-cord.
External links
- Chugai Pharmaceutical Co., Ltd. English version of company homepage
- The transfer of operations of the Company[|permanent dead link|dead link}}]
 |
